Efter 12 måneder sås hos disse patienter en difference på 28% mellem behandlingsgrupperne (67% i gruppen af patienter behandlet med Visudyne mod 39% for placebobehandlede, p < 0, 001); Samme forskel sås efter 24 måneders behandling (59% mod 31%, p < 0, 001).
After 12 months, these patients showed a difference of 28% between treatment groups (67% for Visudyne patients compared to 39% for placebo patients, p < 0.001); the benefit was maintained at 24 months (59% versus 31%, p < 0.001).